Universal Health Services, Inc. research snapshot
UHS AI stock analysis currently reads Universal Health Services as a profitable acute care and behavioral health operator that reported Q2 2026 revenue up 8.3% and net income of $358.4 million, but then lowered its 2026 adjusted EPS forecast on Medicaid reimbursement uncertainty, higher liability reserves, slower de novo ramp, and a behavioral hospital awaiting recertification. At the August 2, 2026 data cutoff, UHS closed at $168.44 on July 31, 2026 with a verified market capitalization near $10.20 billion. The stock trades at about 6.86x trailing earnings and 5.67x EV to EBITDA with a 0.47% dividend yield and a high buyback yield near 6.69%. The UHS AI stock forecast uses scenario ranges rather than a fixed price prediction because Medicaid supplemental programs, payer mix, wage inflation, liability costs, Talkspace acquisition execution, capital spending, and valuation multiples can change quickly.
Current price
$168.44
Market cap
$10.20 billion verified market cap
AI score
68 / 100
Rating
Value-leaning hospital operator facing Medicaid reimbursement uncertainty and an incomplete trend confirmation
Trend status
Rebounded above the 50-day average but still below the 200-day moving average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | UHS owns and operates acute care hospitals, behavioral health facilities, outpatient sites, a health plan, a physician network, and related services that serve recurring patient needs across 40 states, Washington D.C., Puerto Rico, and the United Kingdom. | High |
| Moat | The moat comes from local facility networks, licenses, physician relationships, payer contracts, behavioral health capacity, and operating know-how, but it is limited by regulation, outpatient migration, and payer bargaining power. | Medium |
| Management | CEO Marc Miller has deep UHS operating history and has led the company since 2021. The current test is capital discipline across accelerated buybacks, capacity investment, debt, and the pending Talkspace integration expected to close in mid-August 2026. | Medium-high |
| Financial trend | Q2 2026 net revenues rose 8.3% to $4.638 billion and net income attributable to UHS was $358.4 million, or $5.98 per diluted share. H1 2026 net revenues rose 8.9% to $9.133 billion with net income of $707.1 million. | High |
| Valuation | At $168.44, audited tool math shows about 6.86x trailing EPS, 7.26x forward EPS, 0.56x sales, 5.67x EV to EBITDA, 12.06x price to free cash flow, and a 0.47% dividend yield. | High |
| Technical trend | The stock has rebounded from the 52-week low near $140 to about $168, reclaiming the 50-day average near $151 but staying below the 200-day average near $192, so the long-term trend is not yet confirmed. | Medium |
| Risk level | Main risks include Medicaid supplemental payment reductions under OBBBA beginning in 2028, exchange member losses shifting to self-pay, liability reserve inflation, labor costs, behavioral health regulation, legal exposure, leverage, and de novo ramp execution. | Medium-high |
| AI confidence | Descriptive confidence is high because the Q2 2026 release, earnings call, StockAnalysis, and company filings agree on core facts. Return confidence is lower because Medicaid policy and sentiment can reprice hospital operators fast. | High data confidence |
| Investment certainty | UHS has value characteristics with strong reported earnings and buybacks, but a stronger setup needs Medicaid clarity, controlled liability and labor costs, stable volumes, debt discipline, and a sustained move above the 200-day average. | Medium |
UHS AI stock forecast
The UHS AI stock forecast is scenario-based because hospital earnings depend on admissions, revenue per adjusted admission, behavioral health utilization, wage and liability costs, payer policy, debt, and market multiples. Using the $168.44 price reference, the FY2026 adjusted EPS guidance midpoint near $22.97, and an audited three-year model, the mechanical outcomes are about $240 in a bullish case, $178 in a base case, and $103 in a bearish case before dividends.
$225 to $255 before dividends
More likely if acute care and behavioral health revenue keep growing, Medicaid supplemental programs renew favorably, liability costs stabilize, the Talkspace acquisition closes and scales outpatient and virtual behavioral care, buybacks continue, and the market applies a higher earnings multiple to rising EPS.
$165 to $190 before dividends
More likely if EPS compounds near a mid-single-digit rate, UHS meets its revised 2026 revenue and adjusted EPS guidance, the Cedar Hill and Palm Beach Gardens facilities ramp, the San Antonio behavioral hospital regains certification in 2027, and investors value the company near a 6.5x earnings multiple.
$85 to $105 before dividends
More likely if Medicaid supplemental payment cuts under OBBBA bite from 2028, exchange losses keep shifting patients to self-pay, liability reserves keep rising, behavioral health scrutiny increases, debt rises, de novo ramp disappoints, or the market compresses UHS toward a low earnings multiple.
UHS AI technical analysis
UHS AI technical analysis is cautiously improving as of the August 2, 2026 data cutoff. StockAnalysis showed UHS closing at $168.44 on July 31, 2026, up 3.15% on the day, with the 50-day moving average near $151.24 and the 200-day moving average near $191.75. The stock has bounced from a 52-week low near $140.08 but remains below the 200-day average, and the 52-week high near $246.33 is far overhead.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $168.44 | StockAnalysis close reference from July 31, 2026 at 4:00 PM EDT, used for market-cap and valuation math. |
| Immediate support | $160 to $164 | The July 31 intraday range bottomed near $160.96, marking the first support shelf below the close. |
| Deeper support | $149 to $152 | This brackets the 50-day moving average near $151.24 and the recent breakout zone. |
| Key support | $140 to $142 | The 52-week low near $140.08 is the major downside test. A sustained break would challenge the rebound setup. |
| Near resistance | $176 to $185 | A former consolidation zone and the next overhead area before the longer-term moving averages. |
| Major resistance | $190 to $200 | The 200-day moving average near $191.75 is the main trend test on StockAnalysis style technical feeds. |
| Moving averages | 50-day near $151, 200-day near $192 | Price above the 50-day average supports a rebound, but staying below the 200-day average keeps the long-term trend unconfirmed. |
| Momentum | RSI near 65.26 | StockAnalysis reports RSI near 65, which supports short-term strength while approaching overbought territory. |
| Volume | 20-day volume near 997,000 shares | Volume confirmation matters around the September 15, 2026 dividend payment, the Talkspace close, and Medicaid or guidance updates. |
| Volatility | Watch earnings, Medicaid, liability, labor, and behavioral health headlines | Hospital operators can gap when payer mix, Medicaid payments, staffing costs, compliance risk, or guidance changes. |
| Invalidation | Close below $149, then below $140 | A sustained break below the 50-day average and then the 52-week low would weaken the rebound setup and shift attention to earnings downside risk. |
UHS AI trading strategy
The UHS AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with admissions, revenue per adjusted admission, payer mix, labor and liability costs, behavioral health utilization, debt, and cash flow.
Watch for UHS to hold the $160 to $164 area and reclaim the $176 to $185 zone with improving volume, then test the $190 to $200 long-term moving-average area while Q3 and Q4 results confirm stable admissions, controlled costs, and Medicaid clarity.
A failed move near resistance followed by a close below $149 should reduce trend confidence, especially if earnings commentary points to weaker volumes, higher liability costs, or Medicaid cuts.
If UHS pulls back toward the $149 to $152 area or the low-$140s without a permanent earnings reset, compare the lower price with FY2026 adjusted EPS guidance, TTM free cash flow, debt, peer hospital operators, and 2027 certification expectations.
Do not treat a low P/E as enough if Medicaid assumptions worsen, liability reserves keep rising, behavioral health legal risk grows, or capital spending and the Talkspace deal increase leverage.
Track acute care adjusted admissions, behavioral health adjusted patient days, revenue per adjusted admission and patient day, wage inflation, supply costs, Medicaid supplemental payments and OBBBA timing, liability reserves, buybacks, capex, and Talkspace integration after the expected mid-August 2026 close.
Position sizing should reflect that UHS can look statistically cheap before Medicaid policy, legal, labor, or sentiment risk appears in reported EPS.
Investment research summary
Patients, insurers, employers, and government programs pay UHS because communities need hospital beds, emergency care, acute care procedures, outpatient services, and behavioral health capacity. The business converts recurring healthcare demand into facility revenue and cash flow.
The moat is strongest in local hospital networks, licenses, physician relationships, payer contracts, care capacity, operating know-how, and the behavioral health footprint. It can narrow if payers gain leverage, regulators tighten rules, outpatient migration accelerates, or competitors expand specialty capacity.
The thesis fails if Medicaid supplemental payment cuts under OBBBA bite from 2028, liability reserves keep inflating, exchange losses shift volumes to self-pay, labor costs outrun pricing, admissions soften, Talkspace integration disappoints, or debt and capex reduce financial flexibility.
Marc Miller has deep UHS operating history and has led the company since 2021. The key management test is balancing accelerated buybacks, capacity and de novo investment, the Talkspace acquisition, debt, and compliance and quality discipline.
Hospital and behavioral health demand benefit from aging demographics, chronic disease, mental health demand, acuity, and care-access needs. The offset is that healthcare affordability keeps government, payer, employer, and patient scrutiny high, and outpatient migration changes where revenue is earned.
At $168.44, UHS trades at low earnings, sales, and EV to EBITDA multiples, which gives the stock a value screen. Margin of safety still depends on whether earnings power stays durable after Medicaid policy, liability costs, labor, legal, and leverage risks are considered.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $168.44 close on July 31, 2026 | StockAnalysis UHS overview | August 2, 2026 |
| Market capitalization | $10.20 billion, verified against 60.54 million shares | StockAnalysis UHS statistics | August 2, 2026 |
| Q2 2026 revenue and net income | $4.638 billion revenue and $358.4 million net income attributable to UHS, or $5.98 per diluted share | UHS Q2 2026 results release | August 2, 2026 |
| H1 2026 revenue and net income | $9.133 billion revenue and $707.1 million net income attributable to UHS, or $11.63 per diluted share | UHS Q2 2026 results release | August 2, 2026 |
| Q2 2026 same-facility growth | Acute care revenue +8.2% with adjusted admissions +2.9%; behavioral health revenue +7.4% with adjusted patient days +1.4% | UHS Q2 2026 results release | August 2, 2026 |
| Revised 2026 guidance | Net revenues $18.501 billion to $18.762 billion; adjusted EBITDA net of NCI $2.610 billion to $2.717 billion; adjusted EPS $22.28 to $23.65 | UHS Q2 2026 results release | August 2, 2026 |
| June 30, 2026 balance sheet | $138.8 million cash and $4.85 billion total debt, net leverage about 1.8x | UHS Q2 2026 earnings call | August 2, 2026 |
| Q2 2026 buybacks | 1.89 million shares repurchased for $320 million; about $978 million of authorization remaining | UHS Q2 2026 earnings call | August 2, 2026 |
| Dividend | $0.20 per share quarterly, about $0.80 annualized, paid September 15, 2026 with a September 1, 2026 record date | UHS dividend release | August 2, 2026 |
| Valuation ratios | 6.86x trailing PE, 7.26x forward PE, 0.56x sales, 5.67x EV to EBITDA, 12.06x price to free cash flow, 0.47% dividend yield | StockAnalysis UHS statistics | August 2, 2026 |
| Analyst consensus | Buy rating with an average target of $193.88 and a range of $162 to $290 across 20 analysts | StockAnalysis UHS forecast | August 2, 2026 |
| CEO tenure | Marc D. Miller is CEO, President and Director; Alan B. Miller is Founder and Executive Chairman | StockAnalysis UHS company profile | August 2, 2026 |
This UHS AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of returns. Forecast scenarios are based on available data as of August 2, 2026 and can be wrong if earnings, reimbursement, Medicaid policy, regulation, liability costs, litigation, debt, market liquidity, or investor sentiment changes.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
